Other News To Note
Wednesday, October 16, 2013
• Boston Therapeutics Inc., of Manchester, N.H., said it is sponsoring a research study with the University of Minnesota on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of postmeal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.